Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Neuromyelitis Optica
NCT00904826Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2009
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in neuromyelitis optica (NMO), sponsored by Mayo Clinic. Primary endpoint: Median Number of Neuromyelitis Optica (NMO) Attacks Per Year at 12 months. Started Apr 2009; status: completed.
02
Drugs
eculizumab
03
Conditions
neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT00904826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00904826.